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Multiple myeloma (MM) is the most common form of
plasma cell dyscrasia, characterized by a marked hetero-
geneity of genetic lesions and clinical course. It may
develop from a premalignant condition (monoclonal
gammopathy of undetermined significance, MGUS) or
progress from intramedullary to extramedullary forms
(plasma cell leukemia, PCL). To provide insights into the
molecular characterization of plasma cell dyscrasias and
to investigate the contribution of specific genetic lesions to
the biological and clinical heterogeneity of MM, we
analysed the gene expression profiles of plasma cells
isolated from seven MGUS, 39 MM and six PCL patients
by means of DNA microarrays. MMs resulted highly
heterogeneous at transcriptional level, whereas the
differential expression of genes mainly involved in DNA
metabolism and proliferation distinguished MGUS from
PCLs and the majority of MM cases. The clustering of
MM patients was mainly driven by the presence of the
most recurrent translocations involving the immunoglobu-
lin heavy-chain locus. Distinct gene expression patterns
have been found to be associated with different lesions: the
overexpression of CCND2 and genes involved in cell
adhesion pathways was observed in cases with deregulated
MAF and MAFB, whereas genes upregulated in cases
with the t(4;14) showed apoptosis-related functions. The
peculiar finding in patients with the t(11;14) was the
downregulation of the a-subunit of the IL-6 receptor. In
addition, we identified a set of cancer germline antigens
specifically expressed in a subgroup of MM patients
characterized by an aggressive clinical evolution, a finding
that could have implications for patient classification and
immunotherapy.
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Introduction
Multiple myeloma (MM) is a neoplastic disorder of
plasma cells (PCs) characterized by a highly hetero-
geneous clinical course; it can be preceded by the
presumably premalignant condition called monoclonal
gammopathy of undetermined significance (MGUS),
and may progress from a truly overt intramedullary
form to extramedullary myeloma (plasma cell leukemia,
PCL) (Anderson et al., 2002; Barille-Nion et al., 2003).
MM shows a marked genomic instability involving
both numerical and structural chromosomal aberrations
making it difficult to identify the molecular mechanisms
leading to distinct disease entities, prognostic risk
groups and new targeted therapies. Chromosomal
translocations involving the immunoglobulin heavy-
chain (IGH) locus at 14q32 are a genetic hallmark of
MM: their prevalence varies with the clinical stage of the
disease, being detected in about 50% of MGUS
patients, 60–70% of MM patients and in more than
80% of PCL patients (Ho et al., 2002; Seidl et al., 2003).
Unlike in the case of other hematological malignancies,
multiple loci have been described as being involved in
IGH translocations (Bergsagel and Kuehl, 2001). The
most recurrent are 11q13 (Chesi et al., 1996; Ronchetti
et al., 1999), 4p16.3 (Chesi et al., 1997, 1998b; Richelda
et al., 1997), 16q23 (Chesi et al., 1998a), 6p21 (Shaugh-
nessy et al., 2001) and 20q12 (Hanamura et al., 2001),
which, respectively, lead to the deregulation of CCND1,
FGFR3 and WHSC1(MMSET), MAF, CCND3 and
MAFB genes. Moreover, several reports indicate that the
partner loci are still unknown in about 40% of the cases
with IGH translocations (Seidl et al., 2003), thus suggest-
ing that new deregulated target genes may be identified.
DNA microarray technology has been used in recent
studies to define the gene expression profiles of normal
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and malignant PCs (De Vos et al., 2002; Zhan et al.,
2002, 2003; Davies et al., 2003). It has been shown that
MM PCs can be differentiated from normal PCs on the
basis of the expression of a number of genes, mainly
including oncogenes, growth-related and translation
machinery genes, and it has been reported that at least
two different classes of MM can be identified: one more
similar to MGUS and the other more similar to human
myeloma cell lines (Zhan et al., 2002). A more recent
analysis (Davies et al., 2003) of a limited number of
cases has confirmed previous findings and shown that
the differences between MGUS and MM are smaller
than those between normal and clonal MGUS/MM
PCs. Despite these recent data, a number of biological
and clinical issues remain to be clarified in relation to the
pathogenesis of MM, particularly the molecular events
leading to the transition from MGUS to MM, the
contribution of the activated IGH-translocated genes to
the biological and clinical variability of MM and the
molecular pathways deregulated in patients without
IGH translocations.
To contribute to a better understanding of the
changes in gene expression associated with the neoplas-
tic transformation of PCs in MM, we analysed highly
purified PCs of patients affected by different forms of
plasma cell dyscrasias (MGUS, MM and PCL) using
high-density oligonucleotide microarrays representative
of B18 000 transcripts. The gene expression profiles
were investigated for correlations with clinical para-
meters and distinct types of chromosomal lesions.
Results
Gene expression profiling differentiates MGUS from MM
and PCL PCs
To determine whether gene expression profiling of PCs
from MGUS, MM and PCL patients could identify the
distinct clinical entities, we performed an unsupervised
analysis using the hierarchical clustering algorithm
(Eisen et al., 1998). The 52 samples, described by 2249
highly variable genes, generated a dendrogram (Figure 1)
with two major branches: one branch (green) contained
all the MGUS and five of the 39 MM cases, whereas the
second branch grouped the PCL samples and most of
the MM. Neither the PCL nor MM samples could be
identified as a distinct cluster of the dendrogram,
although 4/6 PCL cases were grouped together. The
MM samples did not cluster according to their clinical–
pathological characteristics, such as clinical stage, the
occurrence of bone lesions or b2-microglobulin levels,
but were mainly grouped on the basis of the presence of
IGH translocations (see below).
In order to identify the genes specifically distinguish-
ing the three different clinical entities, we used a
supervised approach to compare the expression profiles
of MGUS, MM and PCL cases. A total of 120 probe-
sets were differentially expressed in MGUS versus PCL
samples (80 downregulated and 40 upregulated), in
addition to 56 transcripts encoding immunoglobulin
molecules upregulated in MGUS samples (data not
shown). Figure 2a shows the matrix representing the
expression of the identified genes, grouped according to
their predicted biological functions. The main difference
involved the expression of genes related to DNA
replication and metabolism. A number of prolifera-
tion-associated genes were upregulated in the PCL
samples, including genes controlling DNA synthesis
(e.g. NUSAP1, CAD, PCNA, PAICS) and genes
involved in DNA mismatch repair pathway (MCM2,
MCM4, MCM5, MCM6, MSH6). Furthermore, the
PCL PCs showed a selective upregulation of several
genes encoding molecules involved in RNA metabolism
(EXOSC4, RBM10), protein metabolism (PMSC4,
CCT4, CCT3) and nuclear–cytoplasmic transport
(NUP62, NUP210, RAN). Consistently with these
results, the genes whose overexpression has been linked
to growth arrest, such as the negative cell-cycle
regulator GADD45B (Jin et al., 2002), were up-
regulated in the MGUS samples. Interestingly, among
the genes differentially expressed in MGUS versus
PCL PCs, several encode for MYC molecular targets
such as CAD, PRDX3 and GADD45B (Fernandez et al.,
2003).
The comparison of MGUS versus PCL PCs also
showed changes in the expression of genes codifying for
transcriptional repressors or cofactors that play critical
roles in chromatin remodeling, such as ENO1, SAP30
and SMARCA4. This functional category also included
theWHSC1 gene, targeted by t(4;14) (Chesi et al., 1997;
Richelda et al., 1997), which was the most statistically
significant selected gene and showed a 15-fold induction
in PCL versus MGUS. The upregulation of the WHSC1
gene was confirmed by Real-time quantitative RT–PCR
(Q-RT–PCR) analysis (Figure 2b), which showed that
the PCL samples, although negative for t(4;14) and
structural alterations of the 4p16.3 region (Fabris et al.,
2005) had higher levels of WHSC1 transcripts than
MGUS (P¼ 0.0318) and MM patients negative for
t(4;14) (Po0.0001).
When the supervised approach was applied to the
comparison of MM with either PCL or MGUS PCs, we
were able to identify only a few genes specifically
differentiating MM from MGUS (Figure 2c). Nine of
these 15 genes overlapped those identified in the
comparison between MGUS and PCL (Figure 2a, genes
in red), and showed progressive modulation during the
transition from MGUS through MM to the PCL
phenotype. In particular, the chemokine CXCL8 (IL8)
was the most upregulated gene in MGUS together with
the GADD45B and the cytoskeletal organizer VIL2
genes.
MM patients clustering is mainly driven by the presence
of the most recurrent IGH chromosomal translocations
To investigate further the correlation between gene
expression profiles and clinical-pathological character-
istics of MM patients, we performed an unsupervised
analysis on the 39 MM dataset described by the 1899
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Figure 1 Unsupervised analysis of gene expression profiles from purified CD138þ PC samples of seven MGUS, 39 MM and six PCL cases.
The dendrogram was generated using a hierarchical clustering algorithm based on the average-linkage method. In the matrix, each column
represents a sample, and each row a gene. The 52 samples are grouped according to the expression levels of the 2249 most variable genes. The
color scale bar represents the relative gene expression changes normalized by the standard deviation. The clinical and molecular characteristics
of the patients are shown. Stage: 1, stage I; 2, stage II; 3, stage III. Serum b2-microglobulin: N, normal values; P, pathological values (X2.4mg/
l). Bone lesions: 0, none; 1, p3; 2, >3. Patients positive for 13q deletion and for different IGH chromosomal translocations are identified
withþ symbol. t(11;unknown) and t(20;unknown) indicate different rearrangement, respectively targeting the 11q13 and 20q12 loci without any
apparent involvement of Ig loci
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most highly variable genes. Figure 3 shows that the
algorithm grouped the MM samples into two major
clusters: one (orange) mainly including cases negative for
the most recurrent IGH translocations (17/18) and the
other (green) mainly grouping positive cases (18/21).
The association between the clinical–prognostic vari-
ables (clinical stage, serum b2-microglobulin levels, focal
bone lesions, 13q deletion) and these two defined
clusters was evaluated. The only significant correlation
was found between the cluster grouping the patients
positive for IGH translocations and a lower incidence of
bone lesions (P¼ 0.0271). Interestingly, the majority of
Figure 2 Identification of genes specifically expressed in MGUS, MM and PCL by supervised analysis. (a) The genes differentially expressed in
MGUS versus PCL PCs are grouped according to their functional categories and ranked within each category according to their zg score. The
color changes in each row represent the gene expression relative to the mean across the samples. The genes, zg scores and average fold changes
(FC) are indicated. The zg scores and average fold changes are expressed using the MGUS group as baseline. Some of the genes appear more
than once (repeat). Genes overlapping with those reported in Figure 2c are in red. (b) Box plot ofWHSC1/GAPDH mRNA expression levels in
purified MGUS (n¼ 7), MM (n¼ 33), t(4;14)-positive MM (n¼ 6) and PCL (n¼ 6) PCs as detected by Q-RT–PCR analysis (values on the y-axis
are log10 scaled). (c) Identification of genes distinguishing the MGUS and MM samples by supervised analysis performed on seven MGUS and
39 MM patients; the support value used for the analysis was n¼ n02. For GenBank Accession numbers, see Supplementary Table 1
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the patients with focal bone lesions included in this
cluster were characterized by t(11;14) (P¼ 0.0166). Our
database does not indicate any overall correlation
between the occurrence of bone lesions and DKK1 gene
expression levels, recently reported to be associated with
bone disease (Tian et al., 2003). However, DKK1
transcriptional levels tended to become increasingly
discriminant when the IGH translocation-negative
cluster was compared with either the whole IGH
translocation-positive cluster (green, Figure 3;
P¼ 0.0699) or the IGH translocation-positive cluster
without the t(11;14) cases (P¼ 0.0357).
The analysis of the strength of meaningful clusters by
BRB tool quantified the internal stability of the two
major branches (R-index¼ 0.872, D-index¼ 2.9). Cut-
ting the dendrogram at lower levels (i.e. selecting more
than two clusters) led to the most stable subgrouping
(R-index¼ 0.891, D-index¼ 2) when seven clusters were
considered (Figure 3, blue line), thus further supporting
the significance of the clustering associated with the
presence of specific IGH translocations. Within the
translocation-positive group, the samples were clustered
on the basis of the translocation type, being further
subdivided in two main branches: one grouping
mainly t(11;14) samples, and the other containing the
t(4;14) and MAF/MAFB positive cases in two distinct
subgroups. The patients without any known 14q
rearrangements were clustered in three subgroups
(Figure 3), one of which included cases grouping with
PCL (MM-027, 019, 016, 040) as determined by the
unsupervised analysis of the whole samples data set
(Figure 1).
In an attempt to identify gene expression patterns
associated with the main IGH translocations, we
compared the expression profiles of the cases character-
ized by distinct translocations with those of all the other
MMs by means of supervised analyses (Figure 4). Seven
genes were specifically upregulated in the patients
carrying the t(4;14), in addition to FGFR3 and WHSC1
genes, targeted by the translocation (Figure 4, upper
panel). The highest consistency was reached by Kruppel-
like factor 4 (KLF4), a zinc-finger transcriptional
repressor, whose constitutive expression suppresses cell
proliferation by blocking G1/S progression (Chen et al.,
2001). In addition, we found a significant upregulation
of the genes codifying for the DNA-binding protein
CSDA, also known to act as a negative regulator of
transcription through polymerase II promoter (Coles
et al., 1996), and for the NGFR-associated protein 1,
which is involved in apoptosis induction upon nerve
growth factor binding (Mukai et al., 2000).
In all, 19 genes (18 upregulated and one down-
regulated) were identified as differentially expressed in
the three patients carrying translocations deregulating
either MAF or MAFB genes (Figure 4, middle panel).
Among the overexpressed genes, we identified CCND2
and ITGb7, which have recently been reported to be
upregulated in MM as consequence of MAF deregula-
tion (Hurt et al., 2004), as well as several other genes
codifying proteins involved in cell adhesion processes:
the chemokine receptor CX3CR1 (Imaizumi et al., 2004)
and the chemokine CXCL12, specific ligand of the
CXCR4 receptor (Burger et al., 1999), the PKP2
constituent of desmosomal plaque (Chen et al., 2002)
and the toll-like receptor 4 (TLR4), a trans-membrane
receptor expressed in endothelial and B-cells (Aderem
and Ulevitch, 2000). In addition, we also found over-
expression of the ARK5 gene, which codifies for a
protein kinase whose activation triggered by the AKT
pathway induces tumor cells survival during nutrient
starvation (Suzuki et al., 2003). Moreover, these data
were confirmed by analyses of the three PCL samples
carrying deregulated MAF/MAFB and five human
myeloma cell lines positive for t(14;16) translocation
(data not shown).
Immunohistochemical analysis of bone marrow biop-
sies from 10 MM cases selected on the basis of the
microarray data (three positive for translocations
involving MAF or MAFB genes, and seven negative
for CCND2 mRNA expression) showed that only the
PCs of the patients carrying deregulated MAF/MAFB
loci expressed high CCND2 protein levels (Figure 5).
Supervised analysis of cases positive for the t(11;14)
was performed on all but one patient (MM-019 was
excluded because characterized by 4p16.3 locus rear-
rangement and WHSC1 overexpression). Only five
genes with heterogeneous functions resulted specifically
upregulated in patients with t(11;14) in addition to
CCND1 (Figure 4, bottom panel). The only gene
consistently downregulated in CCND1-translocated
patients codifies for the ligand-binding a-subunit of
interleukin-6 receptor (IL6-R, CD126). The analysis of
IL6-R mRNA levels in the entire MMs panel indicated
heterogeneous expression, with the highest levels being
reached in the patients positive for either WHSC1 or
MAF/MAFB deregulation (Figure 6a and b). The
analysis of IL6-R protein in MM subgroups defined
on the basis of the translocations (Figure 6b, right
panel) showed that PCs from patients carrying t(11;14)
had significantly lower amount of CD126 protein in
comparison with the majority of other MM patients,
and particularly the patients characterized by t(4;14) or
MAF genes deregulation.
Finally, a supervised analysis aimed at identifying
the genes differentially expressed by the 13qþ
and 13q cases was performed. No gene could be
identified, even by relaxing analysis criteria, thus
confirming the evidences coming from the unsupervised
clustering.
The expression of multiple tumor-associated antigens
characterizes MM cases clustering with PCL samples
To investigate the changes in gene expression that may
correlate with the clinical progression of MM, we
applied supervised analysis on two groups of patients
identified by unsupervised analysis (Figure 1): one
including five MM cases shown to cluster with MGUS
(MM-045, 064, 055, 063, 072) and the other four cases
clustering with PCL (MM-027, 019, 016, 040).
Cases clustering with MGUS showed downregulation
of eight probe-sets (Figure 7, upper panel), including
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Figure 3 Unsupervised analysis of gene expression profiles from purified CD138þ PC samples of 39 MM cases. The dendrogram was
generated using a hierarchical clustering algorithm based on the average-linkage method. Samples are grouped according to the expression
levels of the 1899 most variable genes. The blue line represents the cutting of the dendrogram at seven clusters level (see text). See Figure 1 for a
description of the matrix
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those for the RUVBL1, CAD and SMARCA4 genes
found expressed at significant lower levels in the MGUS
than in the PCL samples (Figure 2a). In particular, the
CAD gene, previously identified as being significantly
downregulated in MGUS versus both MM and PCL
PCs, was also downregulated in these patients, thus
supporting the relationship of these MM cases to the
MGUS phenotype.
The supervised analysis performed on the four cases
clustering with PCL identified a set of 12 overexpressed
genes (Figure 7, lower panel), mostly codifying for two
known classes of antigenic peptides (GAGE and
MAGE) whose normal expression is restricted to male
germ cells and which are known to be deregulated in a
large variety of tumors including MM (De Backer et al.,
1999; van Baren et al., 1999).
Figure 4 Identification of genes expressed in MM patients carrying specific 14q32 translocations. Supervised analyses were performed using
the Gene@Work software platform to compare the MM patients positive for t(4;14) (upper panel), t(14;16)/t(20;unknown) (middle panel) or
t(11;14) (lower panel) with all of the other MM patients. See Figure 2 for a description of the matrix. The support value n¼ n02 was chosen for
the t(4;14) and t(11;14) analyses; full support was used in the MAF/MAFB analysis. A d-value of 0.05 was used in the t(11;14) analysis. MAF
and MAFB expression levels are shown at the bottom of the middle panel, although the analysis criteria did not allow their selection. The zg
scores and average fold (FC) changes are expressed using the specific translocation group as baseline. For GenBank Accession numbers, see
Supplementary Table 2
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GAGE genes were mapped on chromosome Xq11.23,
reported to be a breakpoint site in synovial sarcoma (de
Leeuw et al., 1994). Given the high degree of genomic
instability that characterizes MM, we investigated by
FISH analysis the region for the presence of any
alterations. The results (data not shown) indicated the
absence of any structural rearrangement targeting this
locus, thus supporting the notion of DNA demethyla-
tion as the primary inducing mechanism of these genes
expression (De Backer et al., 1999).
Discussion
Recent reports concerning the gene expression profiling
of normal and malignant PCs (including MGUS and
Figure 5 Immunohistochemical staining of bone marrow biopsies for CCND2. Representative results of two different MM cases carrying the
MAF/MAFB translocations are reported showing nuclear CCND2 immunoreactivity (brown) in most of the CD138þ PCs (red). Original
magnification:  40
Figure 6 IL6-R expression in MM PCs. (a) IL6-RmRNA expression levels in the 39 MM cases as assessed by microarray analysis. (b) Box plot
of mRNA (left) and CD126 protein (right) expression levels obtained by means of DNA microarray and flow cytometry analyses of CD138þ
PCs, respectively. MM cases are grouped according to the presence of different translocations. MM-019 patient (*) was excluded because
positive for 4p16.3 locus rearrangement and WHSC1 overexpression
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MM but not PCL cases) have suggested that normal
PCs can be differentiated from MGUS and MM,
whereas MGUS and MM cannot be easily distinguished
(Zhan et al., 2002; Davies et al., 2003). One of the major
findings of our study (the first to include PCL cases) is
that the MM phenotype is highly heterogeneous at
transcriptional level. MM and PCL samples are not
distinguishable, and some MM cases show features
closely related to MGUS. Conversely, MGUSs are
defined as a clearly recognizable group, differentiated
from PCLs on the basis of the expression of a large
number of genes mainly involved in controlling cell
proliferation and DNA metabolism, a finding that is
consistent with the more proliferative phenotype of PCL
PCs.
The gene that was most significantly overexpressed in
PCL versus MGUS PCs was WHSC1, which is targeted
by the t(4;14) in MM. The six PCL cases were indeed
negative for structural alterations of the 4p16.3 region,
as evaluated by FISH (Fabris et al., 2005). Although the
function of this gene is still unknown, it has been
suggested that it may be involved in chromatin
remodeling (Huang et al., 1998; Garlisi et al., 2001).
Even though the expression of WHSC1 in PCLs is not
as high as that observed in MM with t(4;14), we can
speculate that its induction may be related to the
activation of the chromatin remodeling pathway as a
consequence of the proliferative activity of PCL PCs.
Overall, this finding suggests that WHSC1 may con-
tribute to the progression of the disease and further
supports its putative role in the neoplastic transforma-
tion of tumors with the t(4;14).
Notably, the majority of genes distinguishing MGUS
from MM were also differentially expressed in MGUS
versus PCL, suggesting that their expression may be
progressively modulated during the transition of PCs
from a preneoplastic to a fully malignant phenotype.
Among these genes, three MYC-targets (CAD, PRDX3
and GADD45B) (Fernandez et al., 2003) were included.
This finding, together with the observation of a
progressive induction of MYC expression associated
with the worsening in the clinical presentation of MM
cases, as assessed by clinical staging (see Supplementary
Figure 1), suggests that the induction of the MYC
pathway may play a role in MM. Moreover, the
finding of IL-8 downregulation in both MM and PCL
samples possibly reflects a progressive independence
of malignant PCs from microenvironment homing
factors.
An interesting result of our study is that the
hierarchical clustering of MM PCs defined two major
groups mainly driven by the presence/absence of the
most recurrent IGH translocations. Previous gene
expression profiling data defined four major MM
clusters (Zhan et al., 2002); however, no information
was provided concerning the correlation with the IGH
translocations. We found no significant association with
the clinical staging or the prognostic parameters
analysed, except for a lower incidence of bone lesions
within the group positive for IGH translocations,
although an overall higher frequency of bone lesions
was correlated with the presence of t(11;14), in line with
recently reported data (Hideshima et al., 2004; Robbiani
et al., 2004).
Figure 7 Identification of genes differentially expressed in ‘MGUS-resembling’ and ‘PCL-resembling’ MM patients. Supervised analyses were
performed comparing the five MM samples clustering with MGUS in the unsupervised analysis (top panel) or the four patients clustering with
PCL (bottom panel) with all the other MM samples. The genes, zg scores and fold changes (FC) are indicated. For GenBank Accession
numbers, see Supplementary Table 3
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The overexpression of FGFR3/WHSC1 in t(4;14) PCs
leads to the upregulation of KLF4, CSDA and
NGFRAP1 genes reported to be involved in the
induction of apoptosis (Coles et al., 1996; Mukai et al.,
2000; Chen et al., 2001). In particular, the overexpres-
sion of KLF4 is intriguing as it has been reported to
mediate the transcriptional repression of the CCND1
promoter (Shie et al., 2000); the low or background
levels of CCND1 found in the patients with the t(4;14)
(data not shown) may therefore be related to its
increased expression. This finding may suggest that
cases with the t(4;14) are characterized by the activation
of proapoptotic pathways, and thus may be more likely
to respond to chemotherapy regimens, consistently with
recently reported data (Stewart et al., 2004). During the
revision process of this manuscript, a study was
published describing the gene expression profiling of
t(4;14) MM cases (Dring et al., 2004) whose results only
partially overlap with our own, probably because of the
different analysis criteria. Instead of the generally used
fold-ratio to describe gene expression changes among
cell subsets, the algorithm applied in our supervised
analysis: (i) discovers gene expression signatures com-
mon to an entire set of experiments; and (ii) considers
the consistency of the expression levels throughout the
phenotype dataset (Califano, 2000).
The downregulation of IL6-R was the most consistent
finding in patients with t(11;14). It has been reported
that IL6-R (CD126) expression is restricted to neoplastic
PCs, with little or no detectable expression by normal
PCs (Rawstron et al., 2000). Our data indicate a
heterogeneous expression of CD126 in MM PCs and
show that patients characterized by t(4;14) or translo-
cated MAF genes exhibit the highest levels. Although
the significance of CD126 expression in neoplastic PCs
remains to be fully clarified, we can argue that lower
levels of IL6-R may reduce the proliferative capacity of
myeloma cells in response to IL-6. It is worth noting
that patients with t(11;14) have improved survival
especially after high-dose therapy (Fonseca et al.,
2002; Moreau et al., 2002), whereas those with t(4;14)
and t(14;16) show a shorter survival after both standard
and high-dose therapy (Keats et al., 2003). Further
studies are warranted to investigate the biological
significance of this finding and its potential clinical
relevance.
Despite the limited number of cases bearing chromo-
somal translocations involving MAF/MAFB loci (con-
sistent with their low incidence in MM), our analysis
identified, as part of the MAF signature, genes that have
been previously reported as transcriptional target of the
MAF gene (Hurt et al., 2004), as well as a number of
genes involved in cell adhesion processes. These data
support the hypothesis that the deregulated expression
of MAF transcription factors targets the interaction
between PCs and the microenvironment through the
activation of cell adhesion and chemotaxis pathways.
Furthermore, the ectopic expression of chemokines
also suggests the presence of the autocrine production
of factors promoting cell adhesion to the bone
marrow. The corroboration of these finding on a larger
number of cases carrying translocations targeting the
MAF genes is needed to assess their potential signifi-
cance.
Finally, MM cases clustering with PCL are character-
ized by the expression of GAGE and MAGE tumor
antigens previously described in MM (van Baren et al.,
1999). In our panel, their expression is specifically
restricted to the MM cases characterized by an
aggressive clinical evolution (course o1 years) and
whose gene expression profiles resemble those of PCLs,
which on the contrary do not show deregulated
expression of these genes. A more aggressive phenotype
has been described as being associated with high levels
of MYC and a lack of CD56 (Sahara et al., 2002;
Rasmussen et al., 2003). Concerning our restricted panel
of cases with a ‘PCL-like’ phenotype, we detected high
levels of MYC expression that only partially correlated
with the lack of CD56 expression (as detected by both
microarray and FACS analysis) (data not shown). The
analysis of a larger number of MM cases is needed to
assess the clinical and therapeutic implications of these
findings, because the expression of these tumor antigens
seem to identify a restricted number of high-risk patients
who may represent good candidates for antibody-
mediated immunotherapy.
In conclusion, our data extend previous evidence that
the marked heterogeneity of MM patients is associated
with a wide spectrum of molecular diversity based on
global gene expression profiling. We showed that this
diversity is mainly driven by different chromosomal
translocations, and identified potential molecular path-
ways specifically related to such genetic lesions. These
data provide a contribution to the investigation of the
molecular pathogenesis of the neoplasia and toward a
molecular-based classification of MM for the identifica-
tion of prognostically relevant entities.
Materials and methods
Patients
Bone marrow samples were collected after informed consent,
during standard diagnostic procedures, from seven MGUS, 39
newly diagnosed MM and six PCL patients. The median age of
the patients (22 female and 30 male subjects) was 65 years
(range 39–82 years). The diagnoses were made by means of
conventional morphology and immunophenotype analyses;
the clinical staging of the 39 MM patients (13 stage I, 12 stage
II and 14 stage III) was defined according to the criteria
described by Durie and Salmon (1975). The monoclonal
components were as follows: IgG (35 patients); IgA (seven);
IgD (one patient); k chain (five); l chain (one patient); double
monoclonal component (three patients); k/l ratio 2.5 for
MGUS, 1.6 for MM and 5 for PCL patients. b2-microglobulin
levels were X2.4mg/l in 34/52 patients. Focal bone lesions
(detected by radiography and/or magnetic resonance imaging)
were present in 26 patients: score 1 was assigned to patients
having p3 lesions (n¼ 18), and 2 to patients with more than
three lesions (n¼ 8). All of the MM and PCL and 2/7 MGUS
patients were characterized by means of fluorescence in situ
hybridization (FISH) for the presence of the most recurrent
IGH translocations: t(4;14)(p16.3;q32) was detected in six MM
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cases; t(11;14)(q13;q32) in 11 (one MGUS, nine MM, one
PCL); t(14;16)(q32;q23) in two MM and one PCL;
t(14;20)(q32;q12) in one PCL and t(6;14)(p21;q32) in one
MM patient. In addition, two cases (MM-054; PCL-002)
showed a CCND1 translocation at the 11q13 and two cases
(MM-069; PCL-006) a MAFB translocation at the 20q not
involving the Ig loci; MM-019 showed a rearrangement in the
region 4p16.3 in addition to a t(11;14) translocation. Finally,
chromosome 13 deletions were found in 17/35 MM, 1/5 PCL
and 1/2 MGUS patients (Fabris et al., 2005).
PCs purification
PCs were purified from bone marrow samples, after red blood
cell lysis with 0.86% ammonium chloride, using CD138
immunomagnetic microbeads according to the manufacturer’s
instructions (MidiMACSs system, Miltenyi Biotec, Auburn,
CA, USA). The purity of the positively selected PCs was
assessed by morphology and flow cytometry and wasX90% in
all cases.
Total RNA extraction and purification
Total RNA was extracted from frozen PCs samples using the
TRIZOLs reagent (Invitrogen, Carlsbad, CA, USA), and
purified using the RNeasys total RNA Isolation Kit (Qiagen,
Valencia, CA, USA). RNA integrity was verified by means of
an Agilent 2100 Bioanalyzer (Agilent Technologies, Wald-
bronn, Germany).
Generation of gene expression profiles
Biotin-labeled cRNA was prepared using the GeneChips
Expression Analysis Technical Manual protocol (Affymetrix
Inc., Santa Clara, CA, USA) as previously described (Klein
et al., 2001). Briefly, 5mg of total RNA were converted into
double-strand cDNA using the Custom SuperScriptt Double-
Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA,
USA). The cDNA was phenol–chloroform extracted with
Phase Lock Gel Lightt (Eppendorf, Hamburg, Germany).
Biotinylated cRNA was generated by means of an in vitro
transcription reaction using the Enzo BioArrayt HighYieldt
RNA transcript Labeling Kit (Enzo Life Science, Inc.,
Farmingdale, NY, USA) and purified using the RNeasys
total RNA Isolation Kit (Qiagen, Valencia, CA, USA). In all,
15mg of fragmented cRNA were hybridized on GeneChips
Human Genome U133A Arrays (Affymetrix Inc., Santa Clara,
CA, USA) after quality checking on GeneChips Test3 Arrays
(Affymetrix Inc., Santa Clara, CA, USA). After scanning, the
images were processed using Affymetrixs MicroArray Suite
(MAS) 5.0 software to generate gene expression intensity
values. The data discussed in this publication have been
deposited in NCBIs Gene Expression Omnibus (GEO, http://
www.ncbi.nlm.nih.gov/geo/) and are accessible through GEO
Series accession number GSE2113.
Microarray data analysis
Arrays normalization was performed using MAS 5.0 ‘global
scaling’ procedure, which normalizes the signals of different
experiments to the same target intensity. The genes whose
expression did not vary across the dataset were not considered
for further analyses. Unsupervised analyses were applied to a
subset of genes whose average change in expression levels
varied at least twofold from the mean across the whole panel.
Hierarchical agglomerative clustering and dendrogram gen-
eration were used to search for natural groupings in the
profiles using the DNAChip Analyzer (Schadt et al., 2001).
Before clustering, the expression values for a gene across all
samples were standardized to have a mean of 0 and a standard
deviation of 1, and these standardized values were used to
calculate correlations between genes and samples, and served
as the basis for merging nodes. The distance between two genes
or individual samples was calculated as one minus Pearson
correlation coefficient between the standardized expression
values, and the average-linkage method (Eisen et al., 1998) was
used for cluster merging.
The presence of significant clusters was assessed by applying
the global test of clustering stability implemented in the BRB
ArrayTools microarray analysis package (McShane et al.,
2002). This statistical method allows computing the strength of
meaningful clusters as a function of the level at which the
dendrogram are ‘cut’ (e.g. depending on the distance at which
the agglomerative process was stopped). Two cluster-specific
reproducibility measures that can aid in assessing the mean-
ingfulness of individual clusters of interest were defined: the
robustness R-index, which measures the proportion of pairs of
samples within a cluster that remain grouped together despite
any data perturbation, and the discrepancy D-index, which
measures the number of added and deleted specimens when
comparing a cluster before and after data perturbation. The
overall cluster stability was computed perturbing the original
data 100 times using artificial experimental noise in the form of
a Gaussian error estimate from the data.
The supervised gene expression analyses were performed
using the Gene@Work software platform, which is a gene
expression analysis tool based on the pattern discovery
algorithm Structural Pattern Localization Analysis by Sequen-
tial Histograms (SPLASH) (Califano, 2000; Klein et al., 2001).
Genes@Work discovers global gene expression ‘signatures’
that are common to an entire set of at least n experiments (the
support set), where n is a user-selectable parameter called the
minimum support. Briefly, differentially expressed genes are
identified by comparing an expected gene expression prob-
ability density p(e), empirically computed from the experi-
mental set with a predefined threshold (the parameter d).
Patterns of differentially expressed genes are then ranked
according to their statistical significance (the pattern score or
z-score). Unless otherwise stated, the value of d for the analysis
was set to 0.02, and the support value was chosen as n¼ n0–1,
being n0 the number of samples in the phenotype set. For each
gene, the statistical significance of the differential expression
across the phenotype and control sets (gene z-score, zg) was
computed using the formula zg¼ (mpmc)/(spþ sc), where mp
and sp are, respectively, the mean and s.d. computed from the
gene expression values for that gene in the phenotype group,
and mc and sc are their corresponding values computed from
the control group.
Q-RT–PCR
In total, 50 ng of total RNA were transcribed into cDNA with
random hexamer primers and analysed according to published
protocol (Heid et al., 1996) using an ABI PRISMt 7700
Sequence Detection System (Applied Biosystems, Foster City,
CA, USA). TaqMan probe and primers were designed using
Primer Express (Applied Biosystems, Foster, CA, USA).
Human WHSC1 (type II, Accession Number AF071593) and
endogenous control GAPDH (TaqMans Pre-Developed Assay
Reagents, PDARs; Applied Biosystems, Foster, CA, USA)
were analysed and the results were expressed asWHSC1 RNA
(ng)/GAPDH RNA (ng).WHSC1 levels were detected with the
forward primer 50-CTCTTGGG TTTAGCAAAAGTTC
ATC-30, the reverse primer 50-TTTCGTCTGCACTTTCG
TATGG-30 and the probe 6-FAM-CCTTAACTGAGAAT
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GAGGTCTCGGACAGC-TAMRA. The reactions were
performed in triplicate.
Immunohistochemistry
Paraffin-embedded sections from bone marrow biopsies fixed
and decalcified in Mielodecs (Bio-Optica, Milan, Italy) were
pretreated with an antigen retrieval solution at 991C for
30min, and then incubated with a 1/100 dilution of anti-
CCND2 polyclonal antibody (Santa Cruz Biotechnology,
Santa Cruz, CA, USA) in Tris-buffered saline (TBS) overnight
at 41C. Detection was performed using the LSABt kit (Dako,
Glostrup, Denmark) according to the manufacturer’s instruc-
tions. Peroxidase activity was developed with 3-3-diaminoben-
zidine-copper sulfate (Sigma Chemical Co., St Louis, MO,
USA). The cases that proved to be immunoreactive for
CCND2 were then incubated with a 1/2000 dilution of anti-
CD138 monoclonal antibody (clone B-B4, Dako, Glostrup,
Denmark) in TBS for 1 h at room temperature. Alkaline
phosphatase activity was developed with the fuchsine substrate
system (Dako, Glostrup, Denmark), according to the manu-
facturer’s instructions.
Flow cytometry analysis
Dual color immunophenotyping analysis was performed on
heparinized bone marrow samples by CD138-FITC (Immuno
Quality Products, Groningen, The Netherlands) and CD126-
PE (Immunotech, Marseilles, France) antibodies. After stain-
ing, the cells were analysed using a FACSCaliburt Flow
Cytometer (Becton Dickinson, Franklin Lakes, NJ USA).
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